With early ties to Rutgers University, I Inspirata, Inc. was acquired Inspira in 2015. Patients with aggressive estrogen receptor-positive breast cancer need chemotherapy in addition to treatment with anti-estrogen therapies. The question for physicians: how to determine how aggressive a cancer is going to be? Ibris Inc. is working to provide that information with a rapid, predictive, prognostic test that can identify ER-positive breast cancer patients requiring chemotherapy. Ibris Inc had been developing technology designed to predict how aggressive a common form of breast cancer is likely to be, helping physicians and patients plan effective therapies that minimize side effects.Ibris can target ER positive breast cancer, Inspirata is a medical imaging company applying their PathologyNEXTTM plan to advance the practice of pathology with digital pathology solutions. These solutions utilize 21st century tools and technologies to increase the speed of cancer detection, diagnosis, and treatment.